Retinal artery occlusion following intravitreal anti-VEGF therapy

Acta Ophthalmologica

Volumn 88, Issue 2, 2010, Pages 263-266

  Von Hanno, Therese ^a   Kinge, Bettina ^b   Fossen, Kristian ^c  

^a NORDLAND HOSPITAL   (Norway)

^b Retinaklinikken Aleris   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Bevacizumab; Macular oedema; Ranibizumab; Retinal artery occlusion; Retinal vein occlusion; VEGF

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; CASE REPORT; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; DRUG SAFETY; HUMAN; MALE; PRIORITY JOURNAL; RETINA ARTERY OCCLUSION; RETINA ISCHEMIA; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; RETINAL ARTERY OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77649227816     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01406.x     Document Type: Article

References (23)

1. Algvere PV, Steén B, Seregard S Kvanta A (2008a A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86 : 482 489.
2. Algvere PV, Kvanta A Seregard S (2008b Shall we use Avastin or Lucentis for ocular neovascularization Acta Ophthalmol 86 : 352 355.
3. Ferrara N (2004 Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 : 581 611. (Pubitemid 39099316)
4. Fung AE, Rosenfeld PJ Reichel E (2006 The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 90 : 1344 1349.
5. González-Pacheco FR, Deudero JJ, Castellanos MC, Castilla MA, Alvarez-Arroyo MV, Yagüe S Caramelo C (2006 Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 291 : 1395 1401.
6. Hood JD, Meininger CJ, Ziche M Granger HJ (1998 VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274 : 1054 1058.
7. Horowitz JR, Rivard A, van der Zee R et al. (1997 Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17 : 2793 2800. (Pubitemid 28016023)
8. Infanger M, Kossmehl P, Shakibaei M et al. (2006 Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: impact of vascular endothelial growth factor. Apoptosis 11 : 749 764.
9. Kamba T McDonald DM (2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 : 1788 1795.
10. Kernt M, Neubauer AS Kampik A (2007 Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85 : 119 120. (Pubitemid 46140172)
11. Lowe GD (2003/2004 Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 33 : 455 457.
12. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, the Tübingen Bevacizumab Study Group Schraermeyer U (2007 Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143 : 995 1002.
13. Priglinger SG, Wolf AH, Kreutzer TC et al. (2007 Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: 6-month results of a prospective trial. Retina 27 : 1004 1012.
14. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY MARINA Study Group (2006 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 : 1419 1431.
15. Scappaticci FA, Skillings JR, Holden SN et al. (2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 : 1232 1239.
16. Shima C, Sakaguchi H, Gomi F et al. (2008 Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86 : 372 376.
17. Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS Larsen M (2008 Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86 : 365 371.
18. Spandau UH, Ihloff AK Jonas JB (2006 Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84 : 555 556.
19. Stahl A, Agostini H, Hansen LL Feltgen N (2007 Bevacizumab in retinal vein occlusion: results of a prospective case series. 1. Graefes Arch Clin Exp Ophthalmol 245 : 1429 1436.
20. Verheul HM Pinedo HM (2007 Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7 : 475 485.
21. ®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 : 81 87.
22. Zachary I (2001 Signalling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280 : 1375 1386.
23. Zhu X, Wu S, Dahut WL Parikh CR (2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49 : 186 193.